Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2006

View Archived Issues

BG-00012 safe and reduces brain lesions in relapsing-remitting multiple sclerosis

Gallium maltolate demonstrates effective and safe antibacterial activity in UTI

Lexicon Genetics and BMS extend neuroscience alliance by two years

Neuroprotective effects of NNZ-2556 target delayed cell death

VAS-203 reduces ICP posttraumatic brain injury and improves neurological function

Dosing completed in phase Ib study of AL-208 for neurodegenerative diseases

ICES and MerLion enter antitumor research collaboration

Picoplatin begins phase I/II study in hormone-refractory metastatic prostate cancer

Vion updates pipeline progress

Inspire to file for phase II testing of epinastine for seasonal allergic rhinitis

CytImmune to begin phase I study of CYT-6091 in advanced cancer

Plans for Yondelis filings

Stressgen Biotechnologies changes name to Nventa Biopharmaceuticals

Large outcomes trial planned for Natrecor

Phase III study of glufosfamide recommended to continue to completion

Delay to initiation of phase IIa study of MEM-3454 in Alzheimer's disease

Target enrollment completed in phase IIa study of E1-I.N.T. in type 1 diabetes

Life Science Pharmaceuticals acquires three monoclonal antibody programs

Thelin recommended for approval in Europe

New therapeutic agents for ocular disorders disclosed

Novel treatments for inflammatory disorders reported in recent patents

Patents claim novel therapeutic agents for respiratory disorders

Preliminary phase I/II results suggest MB-07133 warrants further evaluation in HCC

Different administration schedules tested for ZK-304709, an oral multitarget tumor growth inhibitor

Favorable safety, pharmacokinetic and efficacy findings reported for Coramsine

Safety and maximum tolerated dose of imidacrine defined in phase I trials

Phase I/II study reveals good efficacy and safety for TG-1042 in CTCL and CBCL

Intravesical fusion protein associated with excellent tolerability and activity in bladder cancer

New compounds for the treatment of psychiatric disorders reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...